Biogen Idec (BIIB)

Add a New Bears Reason Company: Biogen Idec (BIIB) Current price: Headline: (100 character max) Analysis: Cancel 0% agree 1 votes edit Profit sharing for Rituxan and Tysabri Top Contributor: James Watson | Created when NASDAQ:BIIB was $53.55 | Edit | History Due to poor negotiating, Biogen Idec receives only about half of the profits for Rituxan and Tysabri under the terms of its co-marketing agreements with Genentech and Elan, respectively. (100 character max) Cancel 0% agree 1 votes edit Poor product diversity Top Contributor: James Watson | Created when NASDAQ:BIIB was $53.55 | Edit | History Biogen Idec has poor product diversity, relying too heavily on blockbuster hits Avonex and Rituxan. Any disruption in the sales of either drug could ruin the company. (100 character max) Cancel

Wikinvest © 2006, 2007, 2008, 2009. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.